Pfizer (NYSE:PFE) Trading Down 2.5%

Pfizer Inc. (NYSE:PFE - Get Free Report) shares were down 2.5% during mid-day trading on Thursday . The company traded as low as $25.58 and last traded at $25.61. Approximately 11,209,758 shares traded hands during trading, a decline of 73% from the average daily volume of 41,489,688 shares. The stock had previously closed at $26.27.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a "buy" rating and a $36.00 price objective for the company. TD Cowen lowered Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, Argus lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $36.33.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a market capitalization of $143.04 billion, a P/E ratio of 71.14, a PEG ratio of 1.19 and a beta of 0.61. The business has a 50-day moving average price of $27.05 and a 200 day moving average price of $28.50.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analysts' expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company's quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.14 earnings per share. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.65%. The ex-dividend date is Thursday, May 9th. Pfizer's dividend payout ratio is currently 466.67%.

Hedge Funds Weigh In On Pfizer

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Equitable Trust Co. lifted its holdings in Pfizer by 60.6% in the first quarter. Equitable Trust Co. now owns 51,038 shares of the biopharmaceutical company's stock valued at $1,416,000 after acquiring an additional 19,255 shares during the period. Advocate Group LLC lifted its stake in shares of Pfizer by 25.3% in the 1st quarter. Advocate Group LLC now owns 295,069 shares of the biopharmaceutical company's stock worth $8,188,000 after purchasing an additional 59,561 shares during the period. Capital Investment Advisory Services LLC boosted its holdings in shares of Pfizer by 12.8% in the first quarter. Capital Investment Advisory Services LLC now owns 110,724 shares of the biopharmaceutical company's stock worth $3,073,000 after buying an additional 12,524 shares during the last quarter. Triumph Capital Management grew its position in Pfizer by 12.0% during the first quarter. Triumph Capital Management now owns 27,807 shares of the biopharmaceutical company's stock valued at $771,000 after buying an additional 2,987 shares during the period. Finally, L.M. Kohn & Company increased its holdings in Pfizer by 4.7% during the first quarter. L.M. Kohn & Company now owns 33,478 shares of the biopharmaceutical company's stock valued at $929,000 after buying an additional 1,511 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.